| (84) |
Designated Contracting States: |
|
AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL
NO PL PT RO RS SE SI SK SM TR |
| (30) |
Priority: |
23.10.2015 EP 15003039
|
| (43) |
Date of publication of application: |
|
29.08.2018 Bulletin 2018/35 |
| (73) |
Proprietors: |
|
- Roche Diagnostics GmbH
68305 Mannheim (DE)
Designated Contracting States:
DE
- F. Hoffmann-La Roche AG
4070 Basel (CH)
Designated Contracting States:
AL AT BE BG CH CY CZ DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR
|
|
| (72) |
Inventors: |
|
- KRAUSE, Friedemann
82377 Penzberg (DE)
- ROLNY, Vinzent
80337 München (DE)
- DAYYANI, Farshid
Irvine, California 92620 (US)
- ESCHERICH, Achim
6052 Hergiswil (CH)
- WEHNL, Birgit
81373 München (DE)
- HE, Ying
81369 München (DE)
- RIEDLINGER, Julia
85521 Ottobrunn (DE)
- HERTH, Felix
69126 Heidelberg (DE)
- MULEY, Thomas
69126 Heidelberg (DE)
|
| (74) |
Representative: Teschemacher, Andrea |
|
Patentanwälte
Isenbruck Bösl Hörschler PartG mbB
Prinzregentenstraße 68
81675 München
81675 München (DE) |
| (56) |
References cited: :
|
| |
|
|
- MULEY TH ET AL: "50: Do preoperatively elevated CYFRA 21-1 or CEA values qualify for
adjuvant chemotherapy in completely resected stage I NSCLC patients?", ANTICANCER
RESEARCH - INTERNATIONAL JOURNAL OF CANCER RESEARCH AND TREATMENT; 12TH INTERNATIONAL
HAMBURG SYMPOSIUM ON TUMOR MARKERS, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH,
GR; HAMBURG, GERMANY, vol. 23, no. 6B, 1 November 2003 (2003-11-01), page 4507, XP008179384,
ISSN: 0250-7005
- MULEY T ET AL: "Increased CYFRA 21-1 and CEA Levels are Negative Predictors of Outcome
in p-Stage I NSCLC", ANTICANCER RESEARCH - INTERNATIONAL JOURNAL OF CANCER RESEARCH
AND TREATMENT, INTERNATIONAL INSTITUTE OF ANTICANCER RESEARCH, GR, vol. 23, no. 5B,
1 September 2003 (2003-09-01), pages 4085-4093, XP008153792, ISSN: 0250-7005
- TAKESHI HANAGIRI ET AL: "Preoperative CYFRA 21-1 and CEA as prognostic factors in
patients with stage I non-small cell lung cancer", LUNG CANCER, ELSEVIER, AMSTERDAM,
NL, vol. 74, no. 1, 6 February 2011 (2011-02-06), pages 112-117, XP028288128, ISSN:
0169-5002, DOI: 10.1016/J.LUNGCAN.2011.02.001 [retrieved on 2011-02-22]
- MULEY T ET AL: "Tumor volume and tumor marker index based on CYFRA 21-1 and CEA are
strong prognostic factors in operated early stage NSCLC", LUNG CANCER, ELSEVIER, AMSTERDAM,
NL, vol. 60, no. 3, 1 June 2008 (2008-06-01), pages 408-415, XP022691011, ISSN: 0169-5002,
DOI: 10.1016/J.LUNGCAN.2007.10.026 [retrieved on 2008-02-20]
- Jan Kulpa ET AL: "Carcinoembryonic Antigen, Squamous Cell Carcinoma Antigen, CYFRA
21-1, and Neuron-specific Enolase in Squamous Cell Lung Cancer Patients", Clinical
Chemistry, 1 November 2002 (2002-11-01), pages 1931-1937, XP055257310, United States
Retrieved from the Internet: URL:http://www.clinchem.org/content/48/11/ 1931.full.pdf
[retrieved on 2016-03-10]
- BLANKENBURG FLORIAN ET AL: "Preoperative CYFRA 21-1 and CEA as prognostic factors
in patients with stage I non-small cell lung cancer: external validation of a prognostic
score", TUMOUR BIOLOGY : THE JOURNAL OF THE INTERNATIONAL SOCIETY FOR ONCODEVELOPMENTAL
BIOLOGY AND MEDICINE, INTERNATIONAL SOCIETY FOR ONCODEVELOPMENTAL BIOLOGY AND MEDICINE,
SWITZERLAND, vol. 29, no. 4, 1 January 2008 (2008-01-01), pages 272-277, XP008179382,
ISSN: 1423-0380, DOI: 10.1159/000152945 [retrieved on 2008-09-09]
- EBERT W ET AL: "Cytokeratin 19 fragment CYFRA 21-1 compared with carcinoembryonic
antigen, squamous cell carcinoma antigen and neuron-specific enolase in lung cancer.
Results of an international multicentre study", EUROPEAN JOURNAL OF CLINICAL CHEMISTRY
AND CLINICAL BIOCHEMISTRY, WALTER DE GRUYTER, BERLIN, DE, vol. 32, no. 3, 1 March
1994 (1994-03-01), pages 189-199, XP008179383, ISSN: 0939-4974, DOI: 10.1515/CCLM.1994.32.3.189
[retrieved on 2009-09-16]
- Macmillan ET AL: "Evaluation of a new tumour marker in patients with non-small-cell
lung cancer: Cyfra 21.1", Br. J. Cancer, 1 January 1994 (1994-01-01), pages 525-528,
XP055257295, Retrieved from the Internet: URL:http://www.ncbi.nlm.nih.gov/pmc/articl
es/PMC1968860/pdf/brjcancer00193-0119.pdf [retrieved on 2016-03-21]
- D. MORO ET AL: "CEA, CYFRA21-1 and SCC in non-small cell lung cancer", LUNG CANCER.,
vol. 13, no. 2, 1 October 1995 (1995-10-01), pages 169-176, XP055257391, NL ISSN:
0169-5002, DOI: 10.1016/0169-5002(95)00485-8
- WIESKOPF B ET AL: "Cyfra 21-1 as a biologic marker of non-small cell lung cancer.
Evaluation of sensitivity, specificity, and prognostic role", CHEST, AMERICAN COLLEGE
OF CHEST PHYSICIANS, US, vol. 108, no. 1, 1 July 1995 (1995-07-01), pages 163-169,
XP002448261, ISSN: 0012-3692
- M Plebani ET AL: "Clinical evaluation of seven tumour markers in lung cancer diagnosis:
can any combination improve the results?", , 1 January 1995 (1995-01-01), pages 170-173,
XP055257408, Retrieved from the Internet: URL:http://www.ncbi.nlm.nih.gov/pmc/articl
es/PMC2034156/pdf/brjcancer00041-0174.pdf [retrieved on 2016-03-10]
- YOSHIKI KOZU ET AL: "Prognostic significance of postoperative serum carcinoembryonic
antigen levels in patients with completely resected pathological-stage I non-small
cell lung cancer", JOURNAL OF CARDIOTHORACIC SURGERY, BIOMED CENTRAL LTD, LO, vol.
8, no. 1, 22 April 2013 (2013-04-22), page 106, XP021145750, ISSN: 1749-8090, DOI:
10.1186/1749-8090-8-106
|
|
